TRN-157 is under clinical development by Theron Pharmaceuticals and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase I drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TRN-157’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TRN-157 overview
TRN-157 is under development for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. The drug candidate is administered through inhalation. The drug candidate acts on long acting M3 muscarinic receptor. It was under development for the treatment of chronic respiratory diseases such as mild and moderate asthma.
Theron Pharmaceuticals overview
Theron Pharmaceuticals is developing long acting m3 muscarinic antagonist for the treatment of chronic respiratory diseases. The company is headquartered in Sunnyvale, California, the US.
For a complete picture of TRN-157’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
